Quantum BioPharma Receives FDA Clearance to Advance Lucid-MS into Phase 2 for Multiple Sclerosis

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received clearance from the U.S. Food and Drug Administration (FDA) to advance its lead multiple sclerosis (MS) candidate, Lucid-MS (Lucid-21-302), into Phase 2 clinical development. The approval of the Investigational New Drug (IND) application allows the company to initiate a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological measures. Trial start-up activities, including site selection, are already underway, with patient enrollment and drug administration expected to begin as quickly as possible.

Lucid-MS is a first-in-class candidate that aims to provide neuroprotection by inhibiting demyelination, the process by which the protective myelin sheath around nerve fibers is damaged. This mechanism distinguishes it from existing MS therapies that primarily focus on modulating the immune system. The drug targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. In preclinical models, Lucid-MS has demonstrated the ability to prevent and reverse myelin breakdown, and prior Phase 1 trials in healthy participants showed a favorable safety profile and good tolerability.

The significance of this FDA clearance lies in the potential to address an unmet need in MS treatment. Current disease-modifying therapies (DMTs) largely work by suppressing or modulating the immune system to reduce inflammation and relapses, but they do not directly promote remyelination or protect neurons from damage. Lucid-MS's neuroprotective approach could offer a complementary or alternative strategy that might slow or even reverse disability progression, a major concern for MS patients. If successful in Phase 2 and subsequent trials, Lucid-MS could become a valuable addition to the MS treatment armamentarium, potentially improving long-term outcomes for millions of people worldwide.

Quantum BioPharma's financial position appears solid, with more than $10 million in cash, digital assets, and liquid investments as of March 31, 2026, which may support the upcoming trial. The company is also advancing other pipeline assets for neurodegenerative and metabolic disorders and alcohol misuse disorders. The FDA's clearance is a key milestone that de-risks the development program and could attract partners or investors.

The announcement underscores the growing interest in neuroprotective therapies for MS and other neurodegenerative conditions. As research continues, the hope is that treatments like Lucid-MS can alter the course of MS by preserving neurological function and improving quality of life. For more information on Quantum BioPharma, visit the company's newsroom at https://ibn.fm/QNTM. The full press release is available at https://ibn.fm/HyWYH.